• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    H.C. Wainwright initiated coverage on AEON Biopharma with a new price target

    8/18/23 8:03:13 AM ET
    $AEON
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $AEON alert in real time by email
    H.C. Wainwright initiated coverage of AEON Biopharma with a rating of Buy and set a new price target of $18.00
    Get the next $AEON alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $AEON

    DatePrice TargetRatingAnalyst
    8/18/2023$18.00Buy
    H.C. Wainwright
    More analyst ratings

    $AEON
    Leadership Updates

    Live Leadership Updates

    See more
    • AEON Biopharma Reports Inducement Grants Under NYSE American LLC Company Guide Section 711

      IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, today announced that, in connection with the appointment of Rob Bancroft as President and Chief Executive Officer, the Company's Compensation Committee of the Board of Directors has approved the grant of inducement awards. The Compensation Committee approved the grant to Mr. Bancroft of a non-qualified stock option to purchase 59,034 shares of AEON Class A common stock under AEON's 2025 Employment Inducement Incentive Award Plan (the "I

      4/21/25 4:10:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Appoints Industry Veteran Rob Bancroft as Chief Executive Officer

      IRVINE, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today the appointment of Rob Bancroft as President and Chief Executive Officer, effective April 29, 2025. Mr. Bancroft will also join AEON's Board of Directors. "We are excited to welcome Rob as the new President and Chief Executive Officer of AEON. He is an exceptional leader who brings a wealth of experience in the therapeutic toxin industry, and a strong track record of building value through the execution of well-defined s

      4/21/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Announces CEO Transition

      – Marc Forth Steps Down as President and CEO to Pursue Another Opportunity; will remain on the Board of Directors – – Jost Fischer, Chairman of AEON, will assume the role of interim CEO – IRVINE, Calif., March 27, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced today a leadership transition under which Marc Forth is stepping down as President and Chief Executive Officer of the Company to pursue another opportunity, effective April 4, 2025. Mr. Forth will continue with the Company as a member of it

      3/27/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Financials

    Live finance-specific insights

    See more
    • AEON Biopharma Reports First Quarter 2025 Financial Results and Provides Corporate Update

      – Continue to conduct analytical studies to prepare for a potential Biosimilar Biological Product Development ("BPD") Type 2a meeting with the FDA in the second half of 2025 – – Pursuing a 351(k) regulatory pathway for ABP-450, which offers potential access to the U.S. market under a single approval for all of BOTOX's currently approved and future therapeutic indications – – Appointed Rob Bancroft as the Company's President and Chief Executive Officer; Mr. Bancroft also joined AEON's Board of Directors – IRVINE, Calif., May 14, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. ("AEON" or the "Company") (NYSE:AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum

      5/14/25 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Announces Topline Results from Phase 2 Trial of ABP-450 (prabotulinumtoxinA) for the Preventive Treatment of Episodic Migraine

      – ABP-450 doses of 150 units and 195 units showed treatment effect of 4.8 days and 5.0 days, respectively, in the mean change from baseline in monthly migraine days (MMD) at weeks 21-24 but did not meet statistical significance vs. placebo because of a much higher-than-expected placebo response of 4.2 days – – Study demonstrated statistical significance on multiple secondary and exploratory endpoints, including the responder analysis of both a >50% and >75% improvement from baseline in MMD – – Totality of the data showed evidence of a dose response favoring the higher 195 units arm, and supports the decision to advance into Phase 3, anticipated in 2H 2024 – – Ongoing Phase 2 trial for the

      10/19/23 4:05:00 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • H.C. Wainwright initiated coverage on AEON Biopharma with a new price target

      H.C. Wainwright initiated coverage of AEON Biopharma with a rating of Buy and set a new price target of $18.00

      8/18/23 8:03:13 AM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $AEON
    SEC Filings

    See more
    • SEC Form 424B5 filed by AEON Biopharma Inc.

      424B5 - AEON Biopharma, Inc. (0001837607) (Filer)

      6/16/25 4:02:09 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • AEON Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - AEON Biopharma, Inc. (0001837607) (Filer)

      6/13/25 4:05:17 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form 10-Q/A filed by AEON Biopharma Inc.

      10-Q/A - AEON Biopharma, Inc. (0001837607) (Filer)

      6/11/25 4:06:45 PM ET
      $AEON
      Biotechnology: Pharmaceutical Preparations
      Health Care